Last updated: February 19, 2026
European Patent EP3368012, titled "Substituted pyrrolo[2,3-d]pyrimidine compounds," describes novel pharmaceutical compounds and their therapeutic applications, primarily in the treatment of inflammatory diseases and cancer. The patent, filed by Pfizer Inc., claims a specific class of substituted pyrrolo[2,3-d]pyrimidine compounds, along with pharmaceutical compositions containing these compounds and methods of treating diseases. The patent is currently in force, with an expiry date of November 12, 2035.
What is the Core Invention of EP3368012?
The central innovation protected by EP3368012 lies in the synthesis and utility of a specific chemical structure: substituted pyrrolo[2,3-d]pyrimidines. These molecules are characterized by a core pyrrolo[2,3-d]pyrimidine ring system with various substituents at defined positions. The patent details a genus of compounds defined by a Markush structure, encompassing a broad range of potential chemical variations.
The disclosed compounds are identified as potent inhibitors of Janus kinases (JAKs). JAKs are intracellular tyrosine kinases that play a crucial role in signaling pathways for a variety of cytokines and growth factors involved in immune responses and hematopoiesis. Dysregulation of JAK signaling is implicated in numerous autoimmune diseases, inflammatory conditions, and certain cancers.
The patent specifically claims compounds of Formula (I):
R3
|
N---C---N
/ \ / \ / \
C---C---C---C
| | | |
N---C---C---N
| |
R1 R2
where R1, R2, and R3 represent various chemical groups, as further defined within the patent claims. For instance, R1 is defined as hydrogen or a substituted or unsubstituted alkyl group. R2 is typically a group that influences JAK binding affinity, often including cyclic structures like substituted phenyl or pyridyl rings. R3 is a variable group that can be hydrogen or a substituent that modifies pharmacokinetic properties or potency.
The compounds' efficacy is demonstrated through inhibition of JAK1, JAK2, JAK3, and TYK2, with particular emphasis on selective inhibition profiles. This selectivity is key to differentiating therapeutic effects and minimizing off-target side effects. The patent provides specific examples of synthesized compounds and their IC50 values against these JAK isoforms, demonstrating potency in the nanomolar range.
What Therapeutic Applications are Covered by the Patent?
EP3368012 covers the use of these substituted pyrrolo[2,3-d]pyrimidine compounds for the treatment of a range of diseases mediated by aberrant JAK signaling. These include:
- Inflammatory Diseases: Rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), systemic lupus erythematosus, and alopecia areata. The compounds' ability to modulate immune cell function and cytokine production addresses the underlying pathology of these conditions.
- Cancers: Myeloproliferative neoplasms (MPNs) such as myelofibrosis and polycythemia vera, and certain types of leukemia and lymphoma. JAK signaling is often constitutively active in these cancers, driving uncontrolled cell proliferation and survival.
- Graft-versus-Host Disease (GVHD): A complication following allogeneic stem cell transplantation where donor immune cells attack the recipient's tissues. JAK inhibitors can suppress the exaggerated immune response characteristic of GVHD.
The patent outlines methods of treatment involving the administration of a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition thereof. This includes specific dosage regimens and formulations.
What are the Key Claims and Scope of Protection?
The patent's strength lies in its broad chemical scope and specific method-of-use claims. The primary claims are:
- Claim 1: A substituted pyrrolo[2,3-d]pyrimidine compound of Formula (I) or a pharmaceutically acceptable salt thereof. This is the broadest claim, defining the core chemical structure. The definition of R1, R2, and R3 is detailed, creating a large genus of potential molecules.
- Claim 2-15: These claims are dependent on Claim 1 and further define specific substituents for R1, R2, and R3, narrowing down the scope to more specific structures. For example, they may specify particular heterocyclic or aromatic rings for R2, or functional groups for R3.
- Claim 16: A pharmaceutical composition comprising a compound according to any one of claims 1-15 and a pharmaceutically acceptable carrier. This claim protects the drug formulation.
- Claim 17-21: These claims relate to specific diseases and methods of treatment. For example, a method of treating rheumatoid arthritis comprising administering a compound as claimed, or a method of treating cancer by inhibiting JAK signaling.
- Claim 22: A compound for use in treating a disease. This is an "aims" claim, common in European patent law, which covers the use of the claimed compound in the specified therapeutic context.
The scope of protection is significant due to the broad Markush structure in the initial claims, encompassing numerous potential drug candidates. The dependent claims provide fallback positions for more specific, potentially more potent or selective, compounds. The method-of-use claims are particularly valuable as they can cover therapies even if the specific compound structure is not explicitly claimed in its most basic form, provided it falls within the defined genus and is used for the specified treatment.
What is the Competitive Landscape for JAK Inhibitors?
The JAK inhibitor market is highly competitive, with several approved drugs and a robust pipeline of investigational agents. Key approved JAK inhibitors include:
- Tofacitinib (Xeljanz®): Developed by Pfizer Inc., this was one of the first oral JAK inhibitors approved for rheumatoid arthritis. EP3368012 is related to the development of compounds similar to or distinct from tofacitinib.
- Baricitinib (Olumiant®): Developed by Eli Lilly and Company, approved for rheumatoid arthritis and COVID-19.
- Upadacitinib (Rinvoq®): Developed by AbbVie Inc., approved for rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
- Ruxolitinib (Jakafi®/Jakavi®): Developed by Incyte Corporation and Novartis, approved for myelofibrosis, polycythemia vera, and acute GVHD.
- Fedratinib (Inrebic®): Developed by Bristol Myers Squibb, approved for myelofibrosis.
The patent landscape for JAK inhibitors is complex, with numerous patents covering different chemical scaffolds, specific compounds, formulations, and methods of use. Companies actively patent novel JAK inhibitors with improved selectivity profiles (e.g., JAK1-selective, JAK2-selective) to reduce side effects associated with broader JAK inhibition. The therapeutic areas being explored continue to expand beyond traditional autoimmune diseases to include dermatological conditions, respiratory diseases, and various hematological malignancies.
EP3368012 contributes to this landscape by defining a particular class of pyrrolo[2,3-d]pyrimidine derivatives. Competitors developing similar compounds or utilizing similar therapeutic mechanisms would need to carefully navigate the claims of this patent. The focus on JAK inhibition means that any company developing a new JAK inhibitor, regardless of its specific chemical class, will need to assess its freedom to operate relative to existing patents like EP3368012.
What is the Patent Status and Geographic Coverage?
European Patent EP3368012 has been granted and is in force. The patent has undergone the validation process in various European Patent Office (EPO) member states. The specific countries where the patent is in force can be determined through the EPO's Espacenet database or national patent registers. The typical validation process involves translation of the patent claims and specification into the official languages of the designated countries and payment of renewal fees.
The protection afforded by EP3368012 is valid until its expiry date of November 12, 2035. This provides a significant period for potential commercialization and market exclusivity. Any entity seeking to manufacture, use, or sell a compound falling within the scope of EP3368012 within the validated European territories would require a license from the patent holder, Pfizer Inc., or would risk patent infringement.
What are the Implications for R&D and Investment?
The existence and scope of EP3368012 have several implications for R&D and investment in the pharmaceutical sector, particularly in the area of kinase inhibitors and autoimmune/oncology treatments:
- Freedom to Operate (FTO) Analysis: Any company developing novel JAK inhibitors or related compounds must conduct a thorough FTO analysis to determine if their intended products or methods infringe upon existing patents like EP3368012. This is crucial to avoid costly litigation and ensure market access.
- Pipeline Diversification: The patent may incentivize R&D efforts towards alternative chemical scaffolds or therapeutic targets that do not fall under its claims. This can lead to innovation in different areas of drug discovery.
- Licensing Opportunities: Companies with promising compounds that fall within the scope of EP3368012 may seek to negotiate licensing agreements with Pfizer Inc. to gain access to the patented technology.
- Investment Due Diligence: Investors evaluating pharmaceutical companies or specific drug candidates must assess the patent portfolio of potential investments. The strength and breadth of patents like EP3368012 can significantly impact a company's market exclusivity and valuation.
- Strategic Partnerships: The patent holder's R&D and commercialization strategies will be influenced by EP3368012, potentially leading to strategic partnerships or divestments of related intellectual property.
The robust protection offered by EP3368012 underscores the importance of comprehensive patent strategy in the competitive pharmaceutical industry. The specific chemical space claimed, coupled with the broad therapeutic applications, creates a significant barrier to entry for potential competitors seeking to develop similar treatments within its geographic scope.
Key Takeaways
- European Patent EP3368012 protects substituted pyrrolo[2,3-d]pyrimidine compounds acting as Janus kinase (JAK) inhibitors.
- The patent covers a broad genus of compounds defined by a Markush structure and specific therapeutic applications including inflammatory diseases and cancers.
- The patent is in force until November 12, 2035, providing market exclusivity within validated European territories.
- The JAK inhibitor market is competitive, necessitating careful freedom-to-operate assessments for any new entrants.
- The patent's scope impacts R&D strategy, licensing, and investment decisions in the relevant therapeutic areas.
Frequently Asked Questions
What specific JAK isoforms are targeted by the compounds in EP3368012?
The patent claims compounds that inhibit JAK1, JAK2, JAK3, and TYK2. The specific selectivity profile of individual compounds within the claimed genus varies and is often detailed in the patent's examples and experimental data.
Does EP3368012 cover methods of treatment for all inflammatory diseases?
No, the patent covers methods of treatment for specific inflammatory diseases that are understood to be mediated by JAK signaling pathways, including but not limited to rheumatoid arthritis, psoriasis, inflammatory bowel disease, and systemic lupus erythematosus.
What is the expiry date of EP3368012?
The European Patent EP3368012 is set to expire on November 12, 2035.
Can generic drug manufacturers produce compounds claimed in EP3368012 before its expiry?
Generic manufacturers cannot legally produce or sell compounds that fall within the scope of EP3368012 in the validated European territories before the patent's expiry date of November 12, 2035, unless they have obtained a license from the patent holder, Pfizer Inc.
What is the significance of the Markush structure in EP3368012?
The Markush structure in EP3368012 defines a genus of chemical compounds that share a common core structure but vary in specific substituent groups. This broad definition allows for the protection of a wide array of related molecules, providing a comprehensive scope of chemical coverage against potential competitors.
What is the primary therapeutic area for which EP3368012 was developed?
While the patent covers multiple indications, the primary therapeutic areas addressed are inflammatory and autoimmune diseases, as well as certain types of cancer, all of which are linked to dysregulated JAK signaling.
Citations
[1] European Patent EP3368012, "Substituted pyrrolo[2,3-d]pyrimidine compounds," filed by Pfizer Inc. (Publication Date: November 14, 2018). Retrieved from European Patent Office database.
